# US 8,771,973 B2 · Methods for treating bleeding disorders using sulfated polysaccharides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,771,973 B2
- Document ID: US8771973B2
- Status: Granted
- Kind: B2
- Application number: 13/111,746
- Filed: 2011-05-19
- Published: 2012-05-24
- Granted: 2014-07-08
- Earliest claimed: 2004-05-27
- Assignees: Baxter Healthcare S.A.; Baxter International Inc.
- Applicants: Kirk W. Johnson
- Inventors: Kirk W. Johnson
- Web page: https://patentgrep.com/patent/US8771973B2

## CPC

- A61K 31/727: Heparin; Heparan
- A61K 31/731: Carrageenans
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K 38/36: Blood coagulation or fibrinolysis factors
- A61K 38/37: Factors VIII
- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or, with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.

## Claims

### Claim 1

A method of identifying a non-anticoagulant sulfated polysaccharide capable of Factor VII-independent acceleration of blood clotting, the method comprising:
measuring clotting time of a Factor VII-deficient plasma sample;
contacting the Factor VII-deficient plasma sample with a non-anticoagulant sulfated polysaccharide, wherein the non-anticoagulant sulfated polysaccharide is pentosan polysulfate or fucoidin, at a concentration of about 10 nM to about 500 nM;
measuring clotting time of the Factor VII-deficient plasma sample after contacting with the non-anticoagulant sulfated polysaccharide; and
comparing the clotting time before contacting the Factor VII-deficient plasma sample with the non-anticoagulant sulfated polysaccharide with the clotting time after contacting the Factor VII-deficient plasma sample with the non-anticoagulant sulfated polysaccharide, wherein a decrease in clotting time after contacting the Factor VII-deficient plasma sample with the non-anticoagulant sulfated polysaccharide compared to before contacting the Factor VII-deficient plasma sample with the non-anticoagulant sulfated polysaccharide indicates that the non-anticoagulant sulfated polysaccharide is capable of Factor VII-independent acceleration of blood clotting.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the non-anticoagulant sulfated polysaccharide is fucoidan.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the clotting time is decreased by at least one-half or more.